Jefferies published a research report concerning Aveo Pharmaceuticals AVEO recent management meeting.
In the report, Jefferies states, “We had the opportunity to meet with AVEO management for an update on their thoughts post-release of top-line TIVO-1 results. We continue to believe that the 12-month progression free survival (PFS) and superior side effect profile will make tivo the new standard of care for renal cell carcinoma (RCC).”
Jefferies maintains its Buy rating and $30 PT on Aveo Pharmaceuticals, which closed Friday at $14.83.
PFSProvident Financial Services Inc
$17.152.94%
Edge Rankings
Momentum70.65
Growth83.60
Quality36.81
Value-
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in